Albireo Provides First Quarter 2018 Business Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- Wall St futures tick higher as oil retreats ahead of inflation data
- Oil falls on weaker demand outlook and higher US stocks
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
- Birkenstock surges on revenue beat, higher full-year outlook
- After-Hours Movers: CSCO, COHR, HLIT, CBRS, STUB, ENS
- After-Hours Movers: CRWV, NBIS, SMCI, LITE, CAVA, HRB
- After-Hours Movers: P, RIOT, BW, RKLB, HIMS, UPWK
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
Albireo Pharma (ALBO) Reports Q1 Loss of $0.15, Miss on Revenues
May 17, 2018 7:31 AM EDTAlbireo Pharma (NASDAQ: ALBO) reported Q1 EPS of ($0.15), versus $1.77 reported last year. Revenue for the quarter came in at $11.2 million versus the consensus estimate of $31.32 million.
The beginning of 2018 has been a landmark period for Albireo, said Ron Cooper, President and Chief Executive... More
